Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...
DNA gyrase, a bacterial type II topoisomerase, is instrumental in maintaining DNA supercoiling during replication and transcription. Owing to its absence in higher eukaryotes, it represents an ...
Acurx Pharmaceuticals’ DNA Polymerase IIIC inhibitors receives US patent: Staten Island, New York Wednesday, February 4, 2026, 15:00 Hrs [IST] Acurx Pharmaceuticals, Inc., a lat ...
STATEN ISLAND, N.Y., Oct. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...
AZoLifeSciences on MSN
Defective DNA protein repair triggers inflammation and premature aging
Unrepaired DNA-protein crosslinks (DPCs) – highly toxic tangles of protein and DNA – cause a process that leads to premature ...
STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...
DNA pol IIIC inhibitors have been clinically validated with the first-generation inhibitor ibezapolstat (IBZ), now entering Phase 3 clinical trials for Clostridioides difficile infection. IBZ has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results